QM · rank #7 · 2026-10-22
CDNA
NASDAQ · $3.35B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +276.85% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +29.5% |
| Profit margin Net profit margin, trailing 12 months. | +24.2% |
| Market cap (USD) Size filter: > $500M required. | $3.35B |
| Anchor (recent) Close on 2026-09-22 | $56.49 |
| Anchor (far) Close on 2025-09-22 | $14.99 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
CareDx is a healthcare molecular diagnostics company providing non-invasive transplant surveillance and specialty oncology testing services, including AlloSure, AlloMap, and NavDx.
Rationale
High momentum (2.77) and strong quality metrics (29.5% ROE, 24.2% profit margin) are supported by 52% Q2 revenue growth, raised full-year guidance, and a debt-free balance sheet with $374 million in cash.
Material risks
- 1Adverse Medicare Local Coverage Determinations (LCDs) or private payer reimbursement reductions could materially impair Testing Services revenues and 74% gross margins.
- 2Commercial competition from Natera's Prospera and potential internalization of testing by hospital transplant labs could reduce testing volumes and erode pricing power.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.